Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community . However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options . Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2 . In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner . In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells . Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.
Index: Antiviral, COVID-19, Drug repurposing, SARS-CoV-2